Form 4 for HBIO HARVARD BIOSCIENCE INC
Accepted 2026-03-18 00:00:00 ET · period of report 2026-03-17 · accession 0001171843-26-001732 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-18 | 2026-03-17 | HBIO | DENELSKY STEPHEN J | Dir | P - Purchase | $4.87 | +10.0K | 21.0K | +91% | +$48.7K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-03-17 | P | A | 10,000 | $4.87 | 21,000 | D | — | — | (F1) Includes (a) 10,000 shares of common stock purchased on March 17, 2026 and (b) 11,000 restricted stock units that fully vest on September 5, 2026. (F2) On March 13, 2026, the common stock of Harvard Bioscience, Inc. underwent a reverse stock split in a ratio of 10-for-1. The 11,000 restricted stock units referenced in Footnote 1(b) were previously reported as covering 110,000 restricted stock units. These numbers have been adjusted to reflect the stock split that occurred on March 13, 2026. |